IPHA

Innate Pharma
IPHA

11 hedge funds and large institutions have $1.49M invested in Innate Pharma in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

less ownership

Funds ownership: →

less funds holding

Funds holding: →

less capital invested

Capital invested by funds: $ → $

less first-time investments, than exits

New positions opened: | Existing positions closed:

60% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 5

Holders
11
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$212K
2
+$49.7K
3
+$11K
4
Barclays
Barclays
United Kingdom
+$1.4K

Top Sellers

1
-$965K
2
-$298K
3
-$38K
4
Bank of America
Bank of America
North Carolina
-$33.5K
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$32K
Name Holding Trade Value Shares
Change 		Change in
Stake
1
$581K
2
$394K
3
$267K
4
$184K
5
$49.7K
6
$11K
7
$2K
8
$1.86K
9
$545
10
$201
11
–
12
–
13
–